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Background: Healthcare claims databases have been used in several studies to characterize the risk and burden of
chemotherapy-induced febrile neutropenia (FN) and effectiveness of colony-stimulating factors against FN. The
accuracy of methods previously used to identify FN in such databases has not been formally evaluated.
Methods: Data comprised linked electronic medical records from Geisinger Health System and healthcare claims
data from Geisinger Health Plan. Subjects were classified into subgroups based on whether or not they were
hospitalized for FN per the presumptive “gold standard” (ANC <1.0×109/L, and body temperature ≥38.3°C or receipt
of antibiotics) and claims-based definition (diagnosis codes for neutropenia, fever, and/or infection). Accuracy was
evaluated principally based on positive predictive value (PPV) and sensitivity.
Results: Among 357 study subjects, 82 (23%) met the gold standard for hospitalized FN. For the claims-based
definition including diagnosis codes for neutropenia plus fever in any position (n=28), PPV was 100% and sensitivity
was 34% (95% CI: 24–45). For the definition including neutropenia in the primary position (n=54), PPV was 87%
(78–95) and sensitivity was 57% (46–68). For the definition including neutropenia in any position (n=71), PPV was
77% (68–87) and sensitivity was 67% (56–77).
Conclusions: Patients hospitalized for chemotherapy-induced FN can be identified in healthcare claims
databases--with an acceptable level of mis-classification–using diagnosis codes for neutropenia, or neutropenia plus
fever.
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Neutropenia is a common side effect of myelosuppressive
chemotherapy. Neutropenia both increases the risk of
infection and diminishes patients’ ability to fight infection.
When neutropenic patients develop fever, a cardinal sign
of infection, the high likelihood of serious consequences
usually results in hospitalization for urgent evaluation,
ongoing monitoring, and administration of intravenous
antibiotics. This common and well-studied complication
of neutropenia is called febrile neutropenia (FN), regard-
less of whether infection is ultimately documented as
the cause of fever. FN--as well as severe or prolonged* Correspondence: dweycker@pai2.com
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reproduction in any medium, provided the ordose-delays, dose-reductions, and discontinuation, inter-
fering with the delivery of optimal treatment and possibly
adversely affecting patient outcomes [1-4]. For these rea-
sons, prophylactic administration of a colony-stimulating
factor (CSF)–which has been shown to reduce the risk of
FN, FN-related hospitalization, and infection, and to reduce
antibiotic use in clinical trials--is recommended concur-
rently with myelosuppressive chemotherapy when FN risk
is estimated to be approximately 20% or greater [3,5-8].
Using public and private healthcare claims databases as
well as hospital discharge records, a number of retrospec-
tive studies have been undertaken to assess the clinical
risk and economic burden of FN requiring hospitalization
in clinical practice and to evaluate the comparative effec-
tiveness of CSF agents against chemotherapy-induced
hospitalized FN [7,9-14]. Because the study databases didl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(ANC) and body temperature, and because there is no
specific diagnosis code for FN, various combinations of
codes for neutropenia, fever, and/or infection were utilized
to identify FN in these studies. The accuracy of these defi-
nitions is unknown, however, and thus it is uncertain
whether the methods of case ascertainment may have
biased study results.
To the best of our knowledge, only one study has
evaluated the test characteristics of claims-based defini-
tions for FN, and this study included a small sample of
older adults with a single tumor type (i.e., non-Hodgkin’s
lymphoma) and evaluated only a single definition [15]. In
light of the dearth of data on the accuracy of the claims-
based definitions that have been used to identify FN
hospitalizations, and because such data may be important
in the design of future studies as well as in reducing bias
in estimators based on definitions that are less than per-




Data were obtained from the MedMining Database, and
spanned the period January 2004 through April 2010.
The MedMining Database comprises electronic medical
records (EMR) for services provided by the Geisinger
Health System (GHS) to more than 2 million persons as
well as healthcare claims for services received within
GHS (as well as selected other health systems) to the
approximately 225,000 members of the Geisinger Health
Plan (GHP).
Data from the GHS EMR include: patient demographics
(e.g., age, sex, race); ambulatory care visits and inpatient
admissions (along with associated diagnoses [ICD-9-CM]
and procedures [ICD-9-CM, HCPCS], and dates of ser-
vice); medication orders/lists; and clinical laboratory and
exam results (including white blood cell count, neutrophil
count, body temperature, and dates of observation). Data
from the GHP healthcare claims database include in-
patient and outpatient diagnoses and procedures, out-
patient drug utilization, and dates of service. EMR and
healthcare claims data can be linked for all GHP members
using unique patient identifiers, and all such data can be
arrayed chronologically to provide a detailed longitudinal
profile of medical and pharmacy services used within
GHS by each GHP member.
Patient-identifying information was encrypted or removed
from the study database prior to its release to the study inves-
tigators, as set forth in the corresponding Data Use Agree-
ment. The study database has been evaluated and certified by
an independent third party to be in compliance with the
Health Insurance Portability and Accountability Act of 1996
(HIPAA) statistical de-identification standards and to satisfythe conditions set forth in Sections 164.514 (a)-(b)1ii of the
HIPAA Privacy Rule regarding the determination and docu-
mentation of statistically de-identified data (45 CFR 46
§46.101). Use of the study database for health services re-
search is therefore fully compliant with the HIPAA Privacy
Rule and federal guidance on PublicWelfare and the Protec-
tion of Human Subjects. Permission to use the data for this
study was requested by study investigators and granted by
MedMining.
Source population
The source population included all GHP members, aged
≥18 years, who began one or more courses of myelosup-
pressive cancer chemotherapy between January 1, 2004
and April 30, 2010. Receipt of chemotherapy was ascer-
tained based on the presence of one or more claims for a
chemotherapy drug or administration, which were identi-
fied using HCPCS and ICD-9-CM codes in the healthcare
claims database. Chemotherapy agents were classified by
level of myelosuppression--any vs none--based on expert
opinion. Regimens including one or more myelotoxic
agents were considered to be myelosuppressive. Evidence
of initiation of a new course of chemotherapy was based
on the earliest claim for chemotherapy during the study
period that was preceded by a 60-day or longer period
without any other claims for chemotherapy; the date of
the earliest such claim was designated as the “index date”.
Among these identified patients, those with evidence of
cancer as indicated by two or more medical claims with a
qualifying 3-digit ICD-9-CM diagnosis code during the
period beginning 60 days prior to the index date were
selected for inclusion in the source population. For
patients with multiple courses of chemotherapy (based on
a gap of ≥60 days between the last administration of
chemotherapy in a given course and the first administra-
tion in the next course) during the study period, all
courses were considered. We excluded patients from the
source population if they were not continuously eligible
for comprehensive medical and drug benefits throughout
the 60-day period prior to chemotherapy initiation. The
classification of chemotherapy agents by level of myelo-
suppression is available in Additional file 1: Table S1 of
the online supplement; cancer codes are available in
Additional file 2: Table S2 of the online supplement.
Chemotherapy cycles and regimens
For each patient in the source population, we identified
each unique cycle within each course of chemotherapy.
The first chemotherapy cycle was defined as beginning
with the date of initiation of chemotherapy (i.e., the index
date) and ending with the first service date for the next
administration of chemotherapy (as evidenced by a med-
ical claim with a corresponding HCPCS or ICD-9-CM
code) occurring at least 7 days--but no more than
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second chemotherapy cycle did not commence prior to
day 60, both the first cycle of chemotherapy and the
course of chemotherapy were considered to have been
completed 30 days following the beginning of the cycle.
The second and all subsequent chemotherapy cycles were
similarly defined, up to a maximum of nine cycles in
total.
Study population
The study population included all patients in the source
population who were admitted to an acute care, short
stay hospital in the GHS during the chemotherapy
course--based on healthcare claims data--and who had
an absolute neutrophil count (ANC) within 1 day of
hospital admission (i.e., the day before, the day of, or the
day after admission)–based on EMR data. Because
chemotherapy-induced FN almost never occurs earlier
than the fifth day of a chemotherapy cycle, and because
some of the aforementioned retrospective studies did
not consider hospitalizations during this period, only
hospitalizations occurring on or after the fifth day of a
chemotherapy cycle were included [11-13].
Febrile neutropenia
The gold standard for identification of FN hospitalization
(i.e., presumptive, for purposes of this retrospective evalu-
ation) was evidence in EMR data of ANC <1.0 × 109/L
and either body temperature ≥38.3°C (101°F) or admi-
nistration of antibiotic or antiviral therapy following
ANC assessment, all having occurred within 1 day of
hospitalization (i.e., the day before, day of, or day after
hospitalization); this definition was considered the pre-
sumptive “gold standard” for purposes of analyses. Receipt
of antibiotics was included in the definition because some
patients (12%) had no recorded body temperature data
during the period within one day of hospital admission,
while others may have had fever prior to admission that
had resolved with antipyretic therapy. We chose our gold
standard definitions of neutropenia and fever to be as con-
sistent as possible with those employed by the National
Comprehensive Cancer Network (NCCN) and Infectious
Diseases Society of America (IDSA), given the limitations
of our database. The NCCN/IDSA defines neutropenia as
ANC <0.5 × 109/L or ANC <1.0 × 109/L with a predicted
decline to <0.5 × 109/L over the next 48 hours. Because
the study database does not include information on antici-
pated decline in ANC over time, and many patients--we
believe--with ANC 0.5–1.0 would be expected to have
ANC <0.5, we defined neutropenia as ANC <1.0 × 109/L
[17,18]. (We note that less authoritative guidelines have
employed the higher threshold in their definition [19,20]).
The NCCN/IDSA defines fever as a single temperature
≥38.3°C orally or ≥38.0°C over 1 hour. Because the studydatabase does not provide information on duration of
temperature readings, and because--we believe--the large
majority of recorded readings were obtained orally,
we defined fever as ≥38.3°C. In addition, because body
temperature readings were not consistently recorded for all
patients, our definition of fever was expanded to include
administration of antibiotic or antiviral therapy, which was
assumed to be a proxy for presence of infection and fever.
Claims-based operational definitions of FN hospitalization
were based on ICD-9-CM inpatient diagnosis codes used in
the aforementioned retrospective studies, and included:
(1) neutropenia (ICD-9 288.0) in the primary position;
(2) neutropenia in any position; (3) neutropenia plus fever
(780.6) in any position; (4) neutropenia or fever in any
position; and (5) neutropenia, fever, or infection in any pos-
ition. (Because the last definition has been used in analyses
to identify all neutropenic complications [including FN]
resulting in hospitalization, its sensitivity was expected to be
greater than the others, although at some loss of specificity
and positive predictive value [PPV].) All of the aforemen-
tioned claims-based definitions were set forth on a priori
basis, and thus were “blinded” to evaluation of the gold
standard; however, operational definitions considering
the ICD-9-CM diagnosis code for pancytopenia (284.1)
(i.e., either neutropenia or pancytopenia) were evaluated on
a “post-hoc” basis.
Each hospitalization was classified as either an FN
hospitalization (FN positive) or a non-FN hospitalization
(FN negative) based on each of the alternative claims-based
definitions and gold standard, respectively. Thus, for each
comparison of a claims-based definition versus the gold
standard, four mutually-exclusive and mutually-exhaustive
results were possible: (1) true-positive (FN positive by both
definitions); (2) false-negative (FN negative by claims-based
definition, FN positive by gold standard); (3) true-negative
(FN negative by both definitions); and (4) false-positive (FN
positive by claims-based definition, FN negative by gold
standard) (Table 1).
Measures and analyses
The accuracy of claims-based definitions for FN, relative
to the gold standard, was evaluated based on their test
characteristics and performance characteristics, principally
PPV and sensitivity; specificity, negative predictive value,
accuracy, and positive and negative likelihood ratios
also were evaluated. Hospitalizations misclassified by
the claims-based definitions (i.e., false-positives and false-
negatives) were further investigated and their diagnosis
codes were reported. Confidence intervals for estimates of
test and performance characteristics were calculated using
techniques of nonparametric bootstrapping (percentile
method) from the study population (1,000 replicates with
replacement). Analyses were conducted using SASW Soft-
ware, Release 9.2 (SAS Institute Inc., Cary, NC).





Test/Performance Characteristic Definition Explanation
Patient Classification, %
True-Positive X / (No. of Patients) × 100%
False-Positive Y / (No. of Patients) × 100%
True-Negative K / (No. of Patients) × 100%
False-Negative Z / (No. of Patients) × 100%
Sensitivity, % X / (X+Z) × 100% % of FN hospitalizations correctly identified by claims-based definition
Specificity, % K / (Y+K) × 100% % of non-FN hospitalizations correctly identified by claims-based definition
Positive Predictive Value (PPV), % X / (X+Y) × 100% % of hosp. identified as FN hosp. by claims-based definition that were true-positives
Negative Predictive Value (NPV), % K / (Z+K) × 100% % of hosp. identified as non-FN hosp. by claims-based definition that were true-negatives
Accuracy, % (X+K) / (No. of Patients) × 100% % of all hospitalizations that were true-positives and true-negatives
Likelihood ratio positive (LR+) [X/(X+Z)] / [1-K/(Y+K)] Odds of hosp. being an FN hosp. when claims-based algorithm is positive
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A total of 3,193 patients received one or more courses of
myelosuppressive chemotherapy during the period of inte-
rest, were continuously eligible for comprehensive medical
and drug benefits during the 60 days prior to initiation of
chemotherapy, and had evidence of cancer (Table 2).
Among these patients, 772 (24%) had a hospitalization
during a course of chemotherapy on or after the fifth day
of a new cycle, and of these patients, 357 (46%) were hospi-
talized within GHS and had available data on ANC within
1 day of hospitalization, and thus were included in the
study population. No patient in the study population had
more than one qualifying hospital admission during the
study period.
Mean age of the study population was 64 (SD: 13) years
and 56% of patients were male (Table 3). Mean ANC at
the time of hospital admission was, on an overall basis,
4.4 × 109/L. Common types of cancer included breast
(10%), lung (19%), colon/rectum (11%), pancreas (8%),
and non-Hodgkin’s lymphoma (11%). Thirty-five percent
of subjects had metastatic disease, and 68% received
chemotherapy with ≥2 myelosuppressive agents. Hospita-
lizations occurred most often in cycle 1 (28%) and cycle 2
(17%). Among the 357 patients in the study population, 82
(23%) met the gold standard for hospitalized FN; 28 (34%)
of the 82 cases had low ANC, fever, and receipt of anti-
microbial therapy, 30 (37%) had low ANC and receipt of
antimicrobial therapy only (5 of the 30 were missing
temperature data), and 24 (29%) had low ANC and fever
only (all within 1 day of hospitalization).
PPV was higher than 80% for claims-based definitions in-
cluding the diagnosis codes for neutropenia plus fever in
any position (PPV, 100%; sensitivity, 34% [95% CI: 24–45])
and neutropenia in the primary position (PPV, 87%
[78–95]; sensitivity, 57% [46–68]) (Table 4). PPV was 77%
(68–87) for the claims-based definition including the
diagnosis code for neutropenia in any position; sensitivity
was 67% (56–77). Sensitivity was highest 87% (79–94) when
identifying hospitalized FN based on a diagnosis code for
neutropenia, fever, or infection; PPV was 35% (28–42). The
addition of the code for pancytopenia to the alternativeTable 2 Selection of source and study populations
Inclusion/exclusion criteria
Source Population
GHP members aged ≥18 years who received myelosuppressive chemothera
plus continuous health benefits during 60-day pretreatment period
plus ≥2 claims with primary cancer diagnosis beginning 60 days prior to
Study Population
plus admission to acute care, short stay hospital during chemotherapy co
plus admitted to hospital within GHS
plus ANC data available within 1 day of hospital admission
GHP: Geisinger Health Plan; GHS: Geisinger Health System; ANC: absolute neutrophclaims-based definitions had minimal impact (i.e., it chan-
ged PPV and sensitivity by ≤3%).
For the claims-based definition identifying FN hospi-
talization based on a diagnosis of neutropenia in any
position, eight of the 27 false-negatives patients had a
diagnosis of septic shock/severe sepsis/septicemia, two
had a diagnosis of pancytopenia, five had diagnoses of
other infections, and 12 had neither a diagnosis of infec-
tion nor fever. Among the 16 false-positives, six patients
had neutropenia (ANC<1,000), but none received antimi-
crobials and three had no temperature data recorded in
the relevant time period. In addition, two patients, of
whom one was febrile, had an ANC > 1,000 but < 1,500,
and one had fever and received antimicrobial therapy with
an ANC of 1,617.
Discussion
Because they are easily accessible and provide readily-
available information on a large number of patients
receiving care in real-world clinical practice, private and
public healthcare claims have been used extensively to
date in health-economic and outcomes research. Such
databases, however, are not without limitations, since
they are not designed to capture certain components of
care (e.g., laboratory results) and thus may lack data on
potentially clinical parameters, which oftentimes are
important for case-ascertainment. Inaccuracies in case-
ascertainment may confer unknown biases in the estima-
tion of study results.
In this study, we evaluated the accuracy of operational
definitions previously used to identify chemotherapy-
induced hospitalization FN in healthcare claims data-
bases. We found that PPV exceeded 80%–the assumed
minimum acceptable threshold--for the definitions
including the diagnosis code for neutropenia in the prin-
cipal position (87%) and diagnosis codes for neutropenia
plus fever (100%), and that PPV was close to the accept-
able threshold for the definition including a diagnosis
code for neutropenia in any position (77%). Among these
definitions, sensitivity was highest for the last one (67%),
although this figure is somewhat lower than that (81%)n (%)
py from 01/01/04 - 4/30/10 3823 (100.0)
3660 (95.7)

































Age (years), mean±SD 64.2±13.0 62.1±13.8 63.3±15.1 62.6±14.8 61.3±16.3 63.0±14.5 65.5±12.3
Male, % 56.0 51.2 42.6 40.9 39.3 44.9 56.2
Body Mass Index (kg/m2), mean±SD 27.3±5.9 27.8±4.5 27.8±4.7 28.1±4.7 28.1±5.7 28.2±5.1 27.3±5.2
N 332 77 51 67 28 74 192
Absolute Neutrophil Count
(cells/L), mean±SD
4.4±5.6 0.2±0.3 0.3±0.9 0.9±3.3 0.2±0.2 1.1±3.5 4.4±6.3
N 357 82 54 71 28 78 201
Cancer
Type %
Bone, Connective Tissue, Skin, Breast
Female Breast 9.8 19.5 18.5 18.3 28.6 17.9 11.9
Other 2.8 1.2 1.9 2.8 3.6 2.6 2.5
Respiratory and Intrathoracic Organs
Trachea, Bronchus, Lung 19.3 17.1 9.3 9.9 14.3 10.3 20.9
Other 1.4 2.4 5.6 4.2 3.6 3.8 2.0
Digestive Organs and Peritoneum
Colon/Rectum 10.9 9.8 5.6 5.6 7.1 5.1 9.5
Pancreas 7.8 1.2 1.9 2.8 0.0 5.1 7.0
Esophagus 2.5 2.4 0.0 0.0 0.0 0.0 1.0
Other 3.1 0.0 0.0 0.0 0.0 0.0 2.0
Non-Hodgkin's Lymphoma 11.2 20.7 25.9 23.9 28.6 24.4 14.9
Genitourinary Organs
Bladder 4.2 3.7 3.7 4.2 0.0 3.8 5.0
Ovarian 3.6 1.2 5.6 4.2 0.0 3.8 3.0
Prostate 2.8 0.0 0.0 0.0 0.0 0.0 3.0
Uterus 1.7 0.0 0.0 1.4 0.0 1.3 0.5





















Table 3 Patient, cancer, and chemotherapy characteristics (Continued)
Lip, Oral Cavity, and Pharnyx 2.0 1.2 0.0 0.0 0.0 0.0 1.5
Blood Cancers 6.7 13.4 13.0 14.1 14.3 14.1 8.0
Hodgkin’s Lymphoma 1.7 1.2 1.9 1.4 0.0 1.3 0.5
Other 5.6 3.7 5.6 5.6 0.0 5.1 5.0
Presence of Metastases, % 35.0 24.4 22.2 21.1 17.9 20.5 26.4
Chemotherapy
No. of Myelosuppressive Drugs in Cycle 1, %
1 32.2 20.6 26.1 27.4 38.1 29.4 29.2
2 47.2 50.7 45.7 46.8 38.1 44.1 49.7
≥3 20.6 28.8 28.3 25.8 23.8 26.5 21.1
Year of Initiation, %
2004-2005 41.7 37.8 42.6 42.3 14.3 39.7 37.3
2006-2007 28.3 28.1 22.2 23.9 32.1 23.1 31.4





















Table 4 Test and performance characteristics of claims–based definitions for febrile neutropenia
Gold standard:
FN: No FN: FN: No FN: FN: No FN: FN: No FN: FN: No FN:
Claims–Based
Definitions:
FN: 47 7 FN: 55 16 FN: 28 0 FN: 55 23 FN: 71 130













True–Positive 13% (10–17) 15% (11–19) 8% (5–11) 15% (11–19) 20% (16–24)
False–Positive 2% (0–3) 4% (2–7) 0% (–––) 6% (4–9) 36% (31–42)
True–Negative 75% (70–79) 73% (68–77) 77% (73–81) 71% (66–75) 41% (36–45)
False–Negative 10% (7–13) 8% (5–10) 15% (11–18) 8% (5–10) 3% (1–5)
Sensitivity, % 57% (46–68) 67% (56–77) 34% (24–45) 67% (56–77) 87% (79–94)
Specificity, % 97% (96–99) 94% (91–97) 100% (–––) 92% (88–95) 53% (47–59)
Positive Predictive Value (PPV), % 87% (78–95) 77% (68–87) 100% (–––) 71% (61–80) 35% (29–42)
Negative Predictive Value (NPV), % 88% (85–92) 91% (87–94) 84% (80–87) 90% (87–94) 93% (89–97)
Accuracy, % 88% (85–91) 88% (85–91) 85% (82–89) 86% (82–90) 61% (55–66)
Likelihood ratio positive (LR+) 22.5 (12.3–68.5) 11.5 (7.6–20.4) ––– 8.0 (5.6–13.4) 1.8 (1.6–2.1)
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evaluation of older adults with non-Hodgkin’s lymphoma
[15]. While sensitivity was improved in our study by in-
cluding codes for fever and infection (87%), PPV (35%) was
lower. We note, however, that this claims-based definition
has most often been employed in comparative effectiveness
studies of CSF agents, in which the focus was not on FN
per se but all neutropenic complications (including severe
neutropenia, afebrile infections in neutropenic patients, as
well as FN) resulting in hospitalization that may be
prevented with prophylaxis. When modifying the gold
standard (i.e., ANC was < 1.5 × 109/L) to capture additional
neutropenic complications–irrespective of whether the
patient was febrile or received antimicrobials–PPV (45%
[38–53]) improved, but sensitivity was lower (81%
[74–88]).
Because no one definition was found to be associated
with both high PPV and high sensitivity, the selection of
a specific definition for identifying hospitalized FN
should be guided by the potential impact of misclassifi-
cation on study outcomes. For example, in studies evalu-
ating the comparative effectiveness of CSFs in clinical
practice, a premium should be placed on a high PPV and
limiting the inclusion of false-positive cases. Since CSFs
can only reduce the risk of infections associated with
true neutropenia, a low PPV would result in a dilution
of the estimated effectiveness of CSF prophylaxis and
estimated relative differences in effectiveness among
agents being studied. A high PPV alone may not be suffi-
cient, however, since if sensitivity is low, analyses may not
be adequately powered to evaluate study objectives. For
other studies, however, such as those in which the outcome
is the cost of FN hospitalization, some misclassification
may be acceptable to the extent that there are offsetting
effects (e.g., if sensitivity and PPV are comparable; and
either costs of false-positives, false-negatives, and true-
positives are similar or costs of false-negatives and false-
positives differ in the opposite direction by the same
degree). The same also may be true for studies characteriz-
ing the clinical risk (i.e., incidence) of FN, for which--given
the limitations of the alternative definitions--the goal
should be to select one that is adequately sensitive and/or
yields a balance between the number of patients who are
misclassified (i.e., as false-positives and false-negatives). It
therefore is essential to consider the importance of the
individual test and performance characteristics of a mea-
sure, relative to the objectives of the study, before selecting
one definition for use, and we recommend considering sev-
eral alternative definitions.
Our study has a number of limitations. First, we ex-
cluded from the study population all patients who were
not hospitalized in a GHS facility (because ANC data were
not available for these patients) and those hospitalized in a
GHS facility who did not have ANC data proximal tohospital admission. Only 35% of patients in the source
population who were hospitalized (including patients trea-
ted inside and outside GHS) had ANC data during the
study time period and thus could be included in the study
population. For these reasons, the number of patients in
the study population was limited to those treated at a
GHS facility and who had ANC data. To the extent that
excluded patients actually had FN and differed from the
study population in important respects, our results may
not be reflective of the larger population. In addition, be-
cause patients who had ANC data proximal to hospital ad-
mission may be selectively different from those who did
not (because of, for example, a history of FN), our study
population may be “enriched” and subject to verification
bias. Second, even for some patients included in the study
population, critical data–especially body temperature–was
missing and thus we used a gold standard based on ANC
and body temperature or administration of antibiotic or
antiviral therapy. Because we used an “imperfect” gold
standard, however, and thus patients’ true status in terms
of FN was unknown, the presence of errors in the classifi-
cation of patients by the gold standard could result in
biased estimates of PPV, sensitivity, and other markers.
Third, since the data for the study come from a single
health plan and coding practices may vary across plans
and geographic regions of the country, the generalizability
of our findings is uncertain. Fourth, the accuracy of
claims-based definitions in identifying FN may vary across
subgroups of patients (e.g., those defined on the basis of
type of cancer or regimen), and thus caution should be
employed when generalizing study results to specific
populations; such subgroup analyses, however, were not
possible given the relatively small size of the study popula-
tion. Fifth, while acknowledging that culture data are less
than perfectly sensitive in identifying infection, the lack of
such information in the data extract precluded any evalu-
ation of the presence of infection in true FN patients
based on positive cultures. Finally, because chemotherapy-
induced FN almost never occurs earlier than the fifth day
of a chemotherapy cycle, and because some of the afore-
mentioned prior studies did not consider hospitalizations
during this period, only hospitalizations occurring on or
after the fifth day of a chemotherapy cycle were included.
Results were not sensitive to this methodological feature
as <5% of all hospitalizations occurred during the first five
days of a chemotherapy cycle.
Conclusion
In summary, the results of our study suggest that patients
hospitalized for chemotherapy-induced FN can be identified
in healthcare claims databases–with an acceptable level of
mis-classification–using the diagnosis code for neutropenia
or diagnosis codes for neutropenia plus fever. Research
investigating the test and performance characteristics of
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(especially those in which ANC, body temperature, and cul-
ture data are available) is needed to verify the findings of
this study, as is research in tumor-specific subgroups.
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